Claims: STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
These are attributed source records, not independent verification of each assertion.
Complete claim record (JSON) · Original source
- title: STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more Source
- url: https://www.statnews.com/pharmalot/2026/09/01/novartis-bristol-trials-paused-pancreatic-cancer-drug-price-pharmalittle-newsletter/?utm_campaign=rss Source
- summary: Hello there from STAT’s London outpost, with Andrew Joseph here filling in for Mr. Pharmalot for a couple of days. The calendar may say September, but just remember, a combination of stubbornness, denial, and determination can keep the summer feeling alive for yet a few more weeks. One thing certainly not on summer break is the headlines. To them we go … President Trump has announced the next round of pricing deals with drugmakers, with nine companies joining the 17 that reached agreements with… Source
- published: Tue, 01 Sep 2026 13:21:06 +0000 Source